Sign In
Buy OCUL
$10.12
+0.145 (+1.45%)
At Close: Jun 23, 2026
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 22'nd Jun 2026
BEDFORD, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript
11:42pm, Wednesday, 17'th Jun 2026
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript
Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program
10:55am, Wednesday, 17'th Jun 2026
Ocular Therapeutix, Inc. (NASDAQ:OCUL) stock is trading higher on Wednesday as the company prepares for its Investor Day, where it will detail its plans for submitting a New Drug Application (NDA) for
Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026
08:45am, Wednesday, 17'th Jun 2026
Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
04:10pm, Monday, 15'th Jun 2026
Ocular Therapeutix is transitioning into a major player in the retinal disease market with its lead program, Axpaxli. Prime Medicine is pioneering a DNA technology to search and replace genetic mutati
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 05'th Jun 2026
BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026
07:00am, Thursday, 04'th Jun 2026
BEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today an
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
07:00am, Tuesday, 02'nd Jun 2026
In addition to Ocular leadership, event to feature prominent retinal disease experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Lejla Vajzovic, MD, FASRS; and Dr. Darius M.
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1
06:06pm, Tuesday, 26'th May 2026
Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases.
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
01:06pm, Tuesday, 19'th May 2026
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 15'th May 2026
BEDFORD, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina
Ocular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
10:00pm, Tuesday, 12'th May 2026
Ocular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 08'th May 2026
BEDFORD, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina
Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call Transcript
02:41pm, Tuesday, 05'th May 2026
Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call Transcript
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
10:16am, Tuesday, 05'th May 2026
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.37 per share a year ago.
